Aethlon Medical (NASDAQ:AEMD) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Aethlon Medical (NASDAQ:AEMD) to a sell rating in a report issued on Saturday.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Aethlon Medical in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Aethlon Medical has an average rating of “Reduce”.

Aethlon Medical Price Performance

NASDAQ:AEMD opened at $3.08 on Friday. The firm has a market capitalization of $2.00 million, a P/E ratio of -0.21 and a beta of 1.41. Aethlon Medical has a one year low of $2.63 and a one year high of $137.00. The company’s 50-day simple moving average is $5.42 and its 200 day simple moving average is $9.07.

Hedge Funds Weigh In On Aethlon Medical

An institutional investor recently bought a new stake in Aethlon Medical stock. Citadel Advisors LLC bought a new position in Aethlon Medical, Inc. (NASDAQ:AEMD) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned about 36.57% of Aethlon Medical as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 1.99% of the company’s stock.

About Aethlon Medical

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.